Navigation Links
Masimo to Present at William Blair & Company 31st Annual Growth Stock Conference
Date:6/3/2011

IRVINE, Calif., June 3, 2011 /PRNewswire/ -- Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the William Blair & Company 31st Annual Growth Stock Conference at the Four Seasons Hotel in Chicago on Wednesday, June 15, at 8:00 a.m. Central Time.  A live audiocast of the presentation will be available on the Masimo website at www.masimo.com.  A replay of the audiocast will be available following the live presentation.

About Masimo Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems.  In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events.  More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion.  In 2005, Masimo introduced rainbow® Pulse CO-Oximetry, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI).  In 2009, Masimo introduced rainbow Acoustic Monitoring, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™).  Masimo's rainbow SET platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options.  Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.Investor Contact:Media Contact:Sheree Aronson

Dana BanksVice President, Investor Relations

Manager, Public RelationsMasimo Corporation

Masimo Corporation(949) 297-7043

(949) 297-7348saronson@masimo.com

dbanks@masimo.comMasimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5, Pulse CO-Oximetry, Pulse CO-Oximeter, and SEDLine  are trademarks or registered trademarks of Masimo Corporation.


'/>"/>

SOURCE Masimo
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care
2. New Clinical Study Finds Masimo Noninvasive Hemoglobin Accurate in Patients with Critically Low Hemoglobin Levels
3. New Johns Hopkins School of Medicine Study Shows Masimo Noninvasive Hemoglobin Monitoring is Accurate During Complex Spine Surgeries
4. Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products
5. Masimo Radical-7(R) and Rad-57(R) Pulse CO-Oximeters(TM) Awarded Airworthiness Release Certification by the United States Army
6. Childrens Hospital Oakland Standardizes to Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Technology
7. Masimo to Present at the Thomas Weisel Partners Healthcare Conference 2009
8. New Study Funded By the National Institutes of Health (NIH) Finds Masimo SpCO(R) May Provide a Noninvasive Measure of Acute Asthma Severity in Children
9. Masimo to Present at the Deutsche Bank 34th Annual Health Care Conference
10. Masimo to Report First Quarter 2009 Financial Results on May 5, 2009
11. New Clinical Study Shows Masimo PVI(TM) Accurately Predicts Fluid Responsiveness in the ICU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
(Date:6/22/2016)... , June 22, 2016 Cell Applications, ... allow them to produce up to one billion ... lot within one week. These high-quality, consistent stem ... preparing cells and spend more time doing meaningful, ... a proprietary, high-volume manufacturing process that produces affordable, ...
Breaking Biology Technology:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
Breaking Biology News(10 mins):